

【Therapeutic category】 249 Other hormone preparations

【Non-proprietary name】 Mitotane

【Safety measure】 PRECAUTIONS should be revised.

A revised description is underlined.

Current	Revision
2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.) Patients receiving spironolactone, pentobarbital, doravirine, ensitrelvir fumaric acid, and lenacapavir	2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.) Patients receiving spironolactone, pentobarbital, <u>elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate, darunavir ethanolate/cobicistat, darunavir ethanolate/cobicistat/emtricitabine/tenofovir alafenamide fumarate, doravirine, dolutegravir sodium/rilpivirine hydrochloride, bictegravir sodium/emtricitabine/tenofovir alafenamide fumarate, rilpivirine, rilpivirine hydrochloride, rilpivirine hydrochloride/emtricitabine/tenofovir alafenamide fumarate,</u> ensitrelvir fumaric acid, and lenacapavir
10. INTERACTIONS 10.1 Contraindications for Co-administration (Do not co-administer with the following)	10. INTERACTIONS 10.1 Contraindications for Co-administration (Do not co-administer with the following)

Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors
Doravirine Ensitrelvir fumaric acid Lenacapavir	The blood concentrations of these drugs may decrease, leading to a reduction in their effects.	The hepatic cytochrome P-450 (CYP3A4)-inducing activity of this drug is considered to promote the metabolism of these drugs.	<u>Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate</u> <u>Darunavir ethanolate/cobicistat</u> <u>Darunavir ethanolate/cobicistat/emtricitabine/tenofovir alafenamide fumarate</u> Doravirine <u>Dolutegravir sodium/rilpivirine hydrochloride</u> <u>Bictegravir sodium/emtricitabine/tenofovir alafenamide fumarate</u> <u>Rilpivirine</u> <u>Rilpivirine hydrochloride</u> <u>Rilpivirine hydrochloride/emtricitabine/</u>	The blood concentrations of these drugs may decrease, leading to a reduction in their effects.	The hepatic cytochrome P-450 (CYP3A4)-inducing activity of this drug is considered to promote the metabolism of these drugs.

This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

	<u>tenofovir alafenamide</u> <u>fumarate</u> Ensitrelvir fumaric acid Lenacapavir		

This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.